The global osteoarthritis therapeutics market size was valued at $6,754.1 million in 2020, and is estimated to reach $15,693.8 million by 2030, growing at a CAGR of 8.8% from 2021 to 2030. Osteoarthritis is one of the most common chronic health conditions characterized by chronic pain and disability with reduced mobility. It is a progressive degenerative disease of joints, caused due to breakdown and eventually loss of cartilage of one or more joints. Cartilage is a connective tissue found in joints between bones such as knees, ankle, and elbow. It helps to provide lubrication and reduce friction in the joint. The goal of osteoarthritis treatment is to elevate the pain and enhance the functional status.
The COVID-19 outbreak is anticipated to have a negative impact on the growth of the global osteoarthritis therapeutics market. Increase in number of COVID-19 cases and decline in use of non-steroidal anti-inflammatory drugs (NSAIDS) and corticosteroid increase the risk of adverse effects. The COVID-19 pandemic has stressed the healthcare systems in the world and increased the need for development of novel therapeutics.
Growth of the osteoarthritis therapeutics market is majorly driven by increase in prevalence of osteoarthritis; advancements in R&D activities for drug development; increase in funding from private & government organizations for development of healthcare sector and research centers; and rise in demand for cell based research activities. For instance, in 2018, the Journal of Stem cells International announced the new approach for the treatment of osteoarthritis by mesenchyme stem cell therapy. As per the same source, it was reported that there are over 500 clinical trials, which are registered on ClinicalTrails.gov to evaluate the safety and efficacy of adult stem cell such as umbilical cord-derived stem cells, pluripotent stem cells, and mesenchyme stem cells for the treatment of osteoarthritis.
Rise in number of approval for drug is anticipated to fuel the growth of the infection disease diagnostic market. For instance, in March 2020, the U.S. Food and Drug Administrative (FDA) accepted the regulatory submission for Tanezumab, which is used for the treatment of patient with chronic pain caused due to moderate to severe osteoarthritis.
In addition, rise in geriatric population fuels the osteoarthritis therapeutics market growth, owing to the fact that aged individuals are more susceptible to osteoarthritis. According to the Journal of EClinicalMedicine, in 2020, it was reported that approximately 22% of the population above the age of 40 years are diagnosed with knee osteoarthritis, globally.
In June 2021, the U.S. Food and Drug Administrative (FDA) announced the approval of CyMedica’s Intellihab system, which is designed for the treatment of pain caused due to debilitating knee osteoarthritis. Thus, technological advancements in osteoarthritis and availability of better treatment option propel the growth of the market. However, high cost of drug used for osteoarthritis and risk associated with the use of nonsteroidal anti-inflammatory drugs, such as stomach ulcer, dizziness, and allergic reaction, are expected to restrict the osteoarthritis therapeutics market growth during the forecast period.
The global osteoarthritis Treatment market segmented into anatomy, drug type, distribution channel, and region. By anatomy, the market is categorized into knee osteoarthritis, hip osteoarthritis, hand osteoarthritis, and small joint osteoarthritis. On the basis of drug type, it is divided into viscosupplementation agents, nonsteroidal anti-inflammatory drugs, analgesics, and corticosteroids. By distribution channel, the market is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Region-wise, the osteoarthritis therapeutics market analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and the rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and the rest of LAMEA).
Depending on anatomy, the knee osteoarthritis segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in prevalence of knee osteoarthritis, advancement in technological development in healthcare sector, increase in geriatric population, and rise in R&D activities in arthritis. However, the hip osteoarthritis segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of obesity, lack of physical activity, and rise in geriatric population.
Top Impacting Factors
On the basis of drug type, the nonsteroidal anti-inflammatory drugs segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to surge in adoption of NSAIDS drugs, increase in launch of new products, and rise in number of prescriptions. However, the viscosupplementation agents segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of osteoarthritis, advancement in R&D activities for development of new viscosupplementation agents, and initiatives taken by government for development of research activities in healthcare sectors.
By distribution channel, the hospital pharmacies segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to initiatives taken by government for advancement of hospital pharmacy and rise in prevalence of osteoarthritis. However, the online pharmacies segment is expected to witness considerable growth during the forecast period due to advancement in technology in the healthcare sector and rise in demand for remote service.
Europe garnered the major share in the osteoarthritis therapeutics market in 2020, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of knee osteoarthritis, increase in number of approval for osteoarthritis, presence of key players, availability of advanced research activities for drug development, and increase in number of clinical study to evaluate safety and efficacy of drug in the region. However, Asia-Pacific is expected to register the highest CAGR of 9.1% from 2021 to 2030, owing to increase in prevalence of osteoarthritis, rise in number of female population, growth in health care expenditures, and lack of physical activities.
The key players operating in the global osteoarthritis therapeutics market include Abbott Laboratories, Bayer AG, Flexion Therapeutics, Inc., and GlaxoSmithKline plc., Horizon Therapeutics plc., Johnson & Johnson, Novartis, Pfizer Inc., Sanofi, and Zimmer Biomet Holding.
Key Market Players
| Report Metric |
Details |
| Report Name |
Osteioarthritis Therapeutics Market |
| The Market size value in 2020 |
6,754.1 Million USD |
| The Revenue forecast in 2030 |
15,693.8 Million USD |
| Growth Rate |
CAGR of 8.8% from 2021 to 2030 |
| Base year considered |
2021 |
| Forecast period |
2021- 2030 |
| Forecast units |
Value (USD) |
| Segments covered |
Type, End-User, Offerings, and Region |
| Report coverage |
Revenue & volume forecast, company share, competitive landscape, growth factors, and trends |
| Geographic regions covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies covered |
Abbott Laboratories, Bayer AG, Flexion Therapeutics, Inc., and GlaxoSmithKline plc., Horizon Therapeutics plc., Johnson & Johnson, Novartis, Pfizer Inc., Sanofi, and Zimmer Biomet Holding. |
Ans. The global osteoarthritis therapeutics market size was valued at $6,754.1 million in 2020, and is estimated to reach $15,693.8 million by 2030.
Ans. The global osteoarthritis therapeutics market is expected to grow at a compound annual growth rate of 8.8% from 2021 to 2030.
Ans. The key players are Abbott Laboratories, Bayer AG, Flexion Therapeutics, Inc., and GlaxoSmithKline plc., Horizon Therapeutics plc., Johnson & Johnson, Novartis, Pfizer Inc., Sanofi, and Zimmer Biomet Holding.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of osteoarthritis
3.5.1.2.Increase in geriatric population
3.5.1.3.Increase in R&D activities for drug development
3.5.2.Restraint
3.5.2.1.Risk associated with the use of non-steroidal anti-inflammatory drugs
3.5.2.1.High cost of drug used for osteoarthritis treatment
3.5.3.Opportunity
3.5.3.1.Change in government policy and increase in healthcare expenditure worldwide
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the osteoarthritis therapeutics market
CHAPTER 4:OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY
4.1.Overview
4.1.1.Market size and forecast
4.2.Knee Osteoarthritis
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Hip Osteoarthritis
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Hand Osteoarthritis
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Small Joint Osteoarthritis
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Viscosupplementation Agents
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Non-steroidal Anti-inflammatory Drugs
5.3.1.Key market trends, growth factors, and opportunitie
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
5.4.Analgesics
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
5.5.Corticosteroids
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region
5.5.3.Market analysis, by country
CHAPTER 6:OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital Pharmacies
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.2.1.Hospital pharmacies by anatomy
6.2.3.Market analysis, by country
6.3.Retail Pharmacies
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.2.1.Retail pharmacies by anatomy
6.3.3.Market analysis, by country
6.4.Online Pharmacies
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.2.1.Online pharmacies by anatomy
6.4.3.Market analysis, by country
CHAPTER 7:OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America osteoarthritis therapeutics market, by anatomy
7.2.3.North America osteoarthritis therapeutics market, by drug type
7.2.4.North America osteoarthritis therapeutics market, by distribution channel
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. osteoarthritis therapeutics market, by anatomy
7.2.5.1.2.U.S. osteoarthritis therapeutics market, by drug type
7.2.5.1.3.U.S. osteoarthritis therapeutics market, by distribution channel
7.2.5.2.Canada
7.2.5.2.1.Canada osteoarthritis therapeutics market, by anatomy
7.2.5.2.2.Canada osteoarthritis therapeutics market, by drug type
7.2.5.2.3.Canada osteoarthritis therapeutics market, by distribution channel
7.2.5.3.Mexico
7.2.5.3.1.Mexico osteoarthritis therapeutics market, by anatomy
7.2.5.3.2.Mexico osteoarthritis therapeutics market, by drug type
7.2.5.3.3.Mexico osteoarthritis therapeutics market, by distribution channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe osteoarthritis therapeutics market, by anatomy
7.3.3.Europe osteoarthritis therapeutics market, by drug type
7.3.4.Europe osteoarthritis therapeutics market, by distribution channel
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany osteoarthritis therapeutics market, by anatomy
7.3.5.1.2.Germany osteoarthritis therapeutics market, by drug type
7.3.5.1.3.Germany osteoarthritis therapeutics market, by distribution channel
7.3.5.2.France
7.3.5.2.1.France osteoarthritis therapeutics market, by anatomy
7.3.5.2.2.France osteoarthritis therapeutics market, by drug type
7.3.5.2.3.France osteoarthritis therapeutics market, by distribution channel
7.3.5.3.UK
7.3.5.3.1.UK osteoarthritis therapeutics market, by anatomy
7.3.5.3.2.UK osteoarthritis therapeutics market, by drug type
7.3.5.3.3.UK osteoarthritis therapeutics market, by distribution channel
7.3.5.4.Italy
7.3.5.4.1.Italy osteoarthritis therapeutics market, by anatomy
7.3.5.4.2.Italy osteoarthritis therapeutics market, by drug type
7.3.5.4.3.Italy osteoarthritis therapeutics market, by distribution channel
7.3.5.5.Spain
7.3.5.5.1.Spain osteoarthritis therapeutics market, by anatomy
7.3.5.5.2.Spain osteoarthritis therapeutics market, by drug type
7.3.5.5.3.Spain osteoarthritis therapeutics market, by distribution channel
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe osteoarthritis therapeutics market, by anatomy
7.3.5.6.2.Rest of Europe osteoarthritis therapeutics market, by drug type
7.3.5.6.3.Rest of Europe osteoarthritis therapeutics market, by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific osteoarthritis therapeutics market, by anatomy
7.4.3.Asia-Pacific osteoarthritis therapeutics market, by drug type
7.4.4.Asia-Pacific osteoarthritis therapeutics market, by distribution channel
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan osteoarthritis therapeutics market, by anatomy
7.4.5.1.2.Japan osteoarthritis therapeutics market, by drug type
7.4.5.1.3.Japan osteoarthritis therapeutics market, by distribution channel
7.4.5.2.China
7.4.5.2.1.China osteoarthritis therapeutics market, by anatomy
7.4.5.2.2.China osteoarthritis therapeutics market, by drug type
7.4.5.2.3.China osteoarthritis therapeutics market, by distribution channel
7.4.5.3.Australia
7.4.5.3.1.Australia osteoarthritis therapeutics market, by anatomy
7.4.5.3.2.Australia osteoarthritis therapeutics market, by drug type
7.4.5.3.3.Australia osteoarthritis therapeutics market, by distribution channel
7.4.5.4.India
7.4.5.4.1.India osteoarthritis therapeutics market, by anatomy
7.4.5.4.2.India osteoarthritis therapeutics market, by drug type
7.4.5.4.3.India osteoarthritis therapeutics market, by distribution channel
7.4.5.5.South Korea
7.4.5.5.1.South Korea osteoarthritis therapeutics market, by anatomy
7.4.5.5.2.South Korea osteoarthritis therapeutics market, by drug type
7.4.5.5.3.South Korea osteoarthritis therapeutics market, by distribution channel
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific osteoarthritis therapeutics market, by anatomy
7.4.5.6.2.Rest of Asia-Pacific osteoarthritis therapeutics market, by drug type
7.4.5.6.3.Rest of Asia-Pacific osteoarthritis therapeutics market, by distribution channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA osteoarthritis therapeutics market, by anatomy
7.5.3.LAMEA osteoarthritis therapeutics market, by drug type
7.5.4.LAMEA osteoarthritis therapeutics market, by distribution channel
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil osteoarthritis therapeutics market, by anatomy
7.5.5.1.2.Brazil osteoarthritis therapeutics market, by drug type
7.5.5.1.3.Brazil osteoarthritis therapeutics market, by distribution channel
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia osteoarthritis therapeutics market, by anatomy
7.5.5.2.2.Saudi Arabia osteoarthritis therapeutics market, by drug type
7.5.5.2.3.Saudi Arabia osteoarthritis therapeutics market, by distribution channel
7.5.5.3.South Africa
7.5.5.3.1.South Africa osteoarthritis therapeutics market, by anatomy
7.5.5.3.2.South Africa osteoarthritis therapeutics market, by drug type
7.5.5.3.3.South Africa osteoarthritis therapeutics market, by distribution channel
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA osteoarthritis therapeutics market, by anatomy
7.5.5.4.2.Rest of LAMEA osteoarthritis therapeutics market, by drug type
7.5.5.4.3.Rest of LAMEA osteoarthritis therapeutics market, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.Abbott Laboratories
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.Bayer AG
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.3.Flexion Therapeutics, Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.GlaxoSmithKline plc.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance.
8.4.6.Key strategic moves and developments
8.5.Horizon Therapeutics plc.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.Johnson & Johnson
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.Novartis
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.Pfizer Inc.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.Sanofi
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.Zimmer Biomet Holding
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020–2030 ($MILLION)
TABLE 02.OSTEOARTHRITIS THERAPEUTICS MARKET FOR KNEE OSTEOARTHRITIS, BY REGION, 2020–2030 ($MILLION)
TABLE 03.OSTEOARTHRITIS THERAPEUTICS MARKET FOR HIP OSTEOARTHRITIS, BY REGION, 2020–2030 ($MILLION)
TABLE 04.OSTEOARTHRITIS THERAPEUTICS MARKET FOR HAND OSTEOARTHRITIS, BY REGION, 2020–2030 ($MILLION)
TABLE 05.OSTEOARTHRITIS THERAPEUTICS MARKET FOR SMALL JOINT OSTEOARTHRITIS, BY REGION, 2020–2030 ($MILLION)
TABLE 06.GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 07.OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY REGION, 2020–2030 ($MILLION)
TABLE 08.OSTEOARTHRITIS THERAPEUTICS MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2020–2030 ($MILLION)
TABLE 09.OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY REGION, 2020–2030 ($MILLION)
TABLE 10.OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY REGION, 2020–2030 ($MILLION)
TABLE 11.GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 12.OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 13.HOSPITAL PHARMACIES MARKET, BY ANATOMY, 2020-2030($MILLION)
TABLE 14.OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 15.RETAIL PHARMACIES MARKET, BY ANATOMY, 2020-2030($MILLION)
TABLE 16.OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 17.ONLINE PHARMACIES MARKET, BY ANATOMY, 2020-2030($MILLION)
TABLE 18.OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 20.NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 21.NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 22.NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 23.U.S. OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 24.U.S. OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 25.U.S. OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 26.CANADA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 27.CANADA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 28.CANADA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 29.MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 30.MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 31.MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 32.EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 33.EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 34.EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 35.EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 36.GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 37.GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 38.GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 39.FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 40.FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 41.FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 42.UK OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 43.UK OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 44.UK OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 45.ITALY OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 46.ITALY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 47.ITALY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 48.SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 49.SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 50.SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 51.REST OF EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 52.REST OF EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 53.REST OF EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 54.ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 55.ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 56.ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 57.ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 58.JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 59.JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 60.JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 61.CHINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 62.CHINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 63.CHINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 64.AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 65.AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 66.AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 67.INDIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 68.INDIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 69.INDIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 70.SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 71.SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 72.SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 76.LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 77.LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 78.LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 79.LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 80.BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 81.BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 82.BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 83.SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 84.SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 85.SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 86.SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 87.SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 88.SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 89.REST OF LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
TABLE 90.REST OF LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 91.REST OF LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 92.ABBOTT: COMPANY SNAPSHOT
TABLE 93.ABBOTT: OPERATING SEGMENT
TABLE 94.ABBOTT: PRODUCT PORTFOLIO
TABLE 95.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 96.BAYER: COMPANY SNAPSHOT
TABLE 97.BAYER: OPERATING SEGMENT
TABLE 98.BAYER: PRODUCT PORTFOLIO
TABLE 99.FLEXION THERAPEUTICS: COMPANY SNAPSHOT
TABLE 100.FLEXION THERAPEUTICS: OPERATING SEGMENT
TABLE 101.FLEXION THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 102.GSK: COMPANY SNAPSHOT
TABLE 103.GSK: OPERATING SEGMENT
TABLE 104.GSK: PRODUCT PORTFOLIO
TABLE 105.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106.HORIZON: COMPANY SNAPSHOT
TABLE 107.HORIZON: OPERATING SEGMENT
TABLE 108.HORIZON: PRODUCT PORTFOLIO
TABLE 109.J&J: COMPANY SNAPSHOT
TABLE 110.J&J: OPERATING SEGMENT
TABLE 111.J&J: PRODUCT PORTFOLIO
TABLE 112.NOVARTIS: COMPANY SNAPSHOT
TABLE 113.NOVARTIS: OPERATING SEGMENT
TABLE 114.NOVARTIS: PRODUCT PORTFOLIO
TABLE 115.NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 116.PFIZER: COMPANY SNAPSHOT
TABLE 117.PFIZER: OPERATING SEGMENT
TABLE 118.PFIZER: PRODUCT PORTFOLIO
TABLE 119.SANOFI: COMPANY SNAPSHOT
TABLE 120.SANOFI: OPERATING SEGMENT
TABLE 121.SANOFI: PRODUCT PORTFOLIO
TABLE 122.ZIMMER BIOMET: COMPANY SNAPSHOT
TABLE 123.ZIMMER BIOMET: OPERATING SEGMENT
TABLE 124.ZIMMER BIOMET: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.OSTEOARTHRITIS THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2020–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2020–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR KNEE OSTEOARTHRITIS, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR HIP OSTEOARTHRITIS, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR HAND OSTEOARTHRITIS, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR SMALL JOINT OSTEOARTHRITIS, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY COUNTRY, 2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2020–2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY COUNTRY, 2020–2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2020–2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2020–2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020–2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2020–2030 (%)
FIGURE 24.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 27.BAYER: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.BAYER: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 29.BAYER: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 30.FLEXION THERAPEUTICS: NET SALES, 2017–2019 ($MILLION)
FIGURE 31.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 33.GSK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 34.HORIZON: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.HORIZON: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 36.HORIZON: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 37.J&J: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.J&J: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39.J&J: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 43.PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 44.PFIZER: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 45.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 46.SANOFI: NET SALES, 2018–2020 ($MILLION)
FIGURE 47.SANOFI: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 48.SANOFI: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 49.ZIMMER BIOMET: NET SALES, 2018–2020 ($MILLION)
FIGURE 50.ZIMMER BIOMET: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 51.ZIMMER BIOMET: REVENUE SHARE, BY REGION, 2020 (%)
$6168
$6929
$10663
HAVE A QUERY?
OUR CUSTOMER
SIMILAR REPORTS
Add to Cart
Add to Cart
Add to Cart
Add to Cart